The ZNF185 antibody targets the zinc finger protein 185 (ZNF185), a member of the LIM domain-containing protein family, which plays roles in cell adhesion, cytoskeletal organization, and signal transduction. ZNF185 is primarily expressed in tissues like the testis, kidney, and prostate, and shares homology with limbic system-associated membrane protein (LSAMP). It interacts with integrin-associated proteins, such as PINCH1. to regulate cell migration and proliferation.
Research on ZNF185 antibodies has focused on elucidating its involvement in cancer progression, particularly prostate and renal cancers, where altered expression correlates with metastasis and poor prognosis. These antibodies are widely used in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to detect ZNF185 localization and expression levels in clinical or experimental samples. Studies suggest ZNF185 may act as a tumor suppressor, with loss of expression linked to enhanced invasive behavior in cancer cells.
ZNF185 antibodies also aid in exploring its role in non-cancer pathologies, including kidney diseases, due to its renal expression. Their specificity enables investigations into ZNF185's structural domains, such as the LIM region critical for protein-protein interactions. However, variability in antibody performance across sample types necessitates validation for consistent experimental outcomes. Overall, ZNF185 antibodies remain vital tools for deciphering the protein's biological functions and therapeutic potential.